Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
Globe Newswire•19/10/2026•08:30 ET
0
Key Highlights
- ➤CK Life Sciences commits $5 million to Dogwood’s private placement.
- ➤Dogwood will issue 4,098,360 shares at $1.22 per share.
- ➤Proceeds extend operational runway through March 2027.
- ➤Halneuron Phase 2b CINP topline data expected in November 2026.
- ➤Investment funds Phase 3 preparatory activities for Halneuron.
Expert Statements
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
“This investment by CK Life Sciences reflects their confidence in the potential of Halneuron(®) and our HAL-CINP Phase 2b program.”
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
“Upon closing, these proceeds are expected to extend our runway through March 2027, by which time we expect to finalize a pivotal Phase 3 program design for Halneuron(®) in CINP.”
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
“We look forward to reporting topline data from the HAL-CINP trial in the coming weeks and value CK Life Sciences’ deepening commitment to Dogwood and Halneuron(®).”
- Largest Shareholder Increases Position as Dogwood Advances Halneuron(®) Toward Topline Phase 2b Data Readout in November 2026 -
- Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities -
Get started
Create a free account to read the full story.